Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.

Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC.

Int J Cancer. 2008 Aug 15;123(4):867-73. doi: 10.1002/ijc.23529.

2.

Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study.

Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):959-65. doi: 10.1158/1055-9965.EPI-07-0750.

3.

Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?

Fitzgerald TL, Dennis SO, Kachare SD, Vohra NA, Zervos EE.

Surgery. 2015 Aug;158(2):466-71. doi: 10.1016/j.surg.2015.03.042.

PMID:
26013986
4.

Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study.

Jung YS, Yun KE, Chang Y, Ryu S, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Park DI.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1406-13. doi: 10.1158/1055-9965.EPI-14-0132.

5.

Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.

Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD; Knowledge NETwork..

Endocr Relat Cancer. 2014 May 6;21(3):R153-63. doi: 10.1530/ERC-13-0125. Review.

6.
7.

Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis.

Haugvik SP, Hedenström P, Korsæth E, Valente R, Hayes A, Siuka D, Maisonneuve P, Gladhaug IP, Lindkvist B, Capurso G.

Neuroendocrinology. 2015;101(2):133-42. doi: 10.1159/000375164. Review.

9.

Risk factors for pancreatic cancer: case-control study.

Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi R, Jiao L, Li D.

Am J Gastroenterol. 2007 Dec;102(12):2696-707.

10.

A large prospective study of risk factors for adenocarcinomas and malignant carcinoid tumors of the small intestine.

Cross AJ, Hollenbeck AR, Park Y.

Cancer Causes Control. 2013 Sep;24(9):1737-46. doi: 10.1007/s10552-013-0251-8.

11.

Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.

Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, Petersen GM.

Pancreas. 2014 Nov;43(8):1219-22. doi: 10.1097/MPA.0000000000000234.

12.

Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.

Ellis L, Shale MJ, Coleman MP.

Am J Gastroenterol. 2010 Dec;105(12):2563-9. doi: 10.1038/ajg.2010.341.

PMID:
20823835
13.

Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis.

Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G.

Ann Oncol. 2016 Jan;27(1):68-81. doi: 10.1093/annonc/mdv505. Review.

PMID:
26487581
14.

Family history of cancer and risk of esophageal and gastric cancers in the United States.

Dhillon PK, Farrow DC, Vaughan TL, Chow WH, Risch HA, Gammon MD, Mayne ST, Stanford JL, Schoenberg JB, Ahsan H, Dubrow R, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr.

Int J Cancer. 2001 Jul 1;93(1):148-52.

15.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB.

J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.

PMID:
18565894
16.

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A.

J Endocrinol Invest. 2012 Oct;35(9):817-23. doi: 10.3275/8102.

PMID:
22080849
17.

Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.

[No authors listed]

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 7):10-1. Review. No abstract available.

PMID:
27168105
19.

Epidemiology of gastroenteropancreatic neuroendocrine tumours.

Fraenkel M, Kim MK, Faggiano A, Valk GD.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):691-703. doi: 10.1016/j.bpg.2013.01.006. Review.

PMID:
23582913
20.

A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.

Modlin IM, Champaneria MC, Chan AK, Kidd M.

Am J Gastroenterol. 2007 Jul;102(7):1464-73.

PMID:
17391319
Items per page

Supplemental Content

Support Center